Ara Toshiaki, Maeda Yoshihiro, Fujinami Yoshiaki, Imamura Yasuhiro, Hattori Toshimi, Wang Pao-Li
Department of Pharmacology, Matsumoto Dental University, Shiojiri, Nagano, Japan.
Biol Pharm Bull. 2008 Jun;31(6):1141-4. doi: 10.1248/bpb.31.1141.
In the present study, we investigated the anti-inflammatory effects of a Kampo medicine Shosaikoto (TJ-9) using in vitro periodontal disease model, in which human gingival fibroblasts (HGFs) treated with lipopolysaccharide (LPS) from Porphyromonas gingivalis (PgLPS) produce IL-6, IL-8 and prostaglandin E2 (PGE2). Treatment with PgLPS (10 ng/ml), TJ-9 (up to 1 mg/ml) and their combinations for 24 h did not affect the viability of HGFs. Moreover, TJ-9 did not alter LPS-induced IL-6 and IL-8 productions. However, TJ-9 significantly suppressed LPS-induced PGE2 production in a dose-dependent manner but TJ-9 alone did not affect basal PGE2 level. Western blotting demonstrated that TJ-9 decreased cyclooxygenase-2 (COX-2) expression in a dose-dependent manner but not phospholipase A2. Moreover, TJ-9 selectively and dose-dependently inhibited COX-2 activity. These results suggest that TJ-9 decreased PGE2 production by inhibition of both COX-2 expression and activity and that TJ-9 may be useful to improve gingival inflammation in periodontal disease.
在本研究中，我们使用体外牙周疾病模型研究了汉方药物小柴胡汤（TJ - 9）的抗炎作用，在该模型中，用牙龈卟啉单胞菌的脂多糖（PgLPS）处理人牙龈成纤维细胞（HGFs）会产生白细胞介素 - 6（IL - 6）、白细胞介素 - 8（IL - 8）和前列腺素E2（PGE2）。用PgLPS（10 ng/ml）、TJ - 9（最高1 mg/ml）及其组合处理24小时对HGFs的活力没有影响。此外，TJ - 9并未改变LPS诱导的IL - 6和IL - 8的产生。然而，TJ - 9以剂量依赖的方式显著抑制LPS诱导的PGE2产生，但TJ - 9单独使用并不影响基础PGE2水平。蛋白质印迹法表明，TJ - 9以剂量依赖的方式降低环氧化酶 - 2（COX - 2）的表达，但不影响磷脂酶A2。此外，TJ - 9选择性地且剂量依赖性地抑制COX - 2活性。这些结果表明，TJ - 9通过抑制COX - 2的表达和活性降低PGE2的产生，并且TJ - 9可能有助于改善牙周疾病中的牙龈炎症。
